PURPOSE: To describe the absolute neutrophil counts (ANC) profile in breast cancer patients receiving high-dose of chemotherapy and peripheral blood stem-cells (PBSC) transplantation. METHODS: Data from 41 subjects receiving cyclophosphamide, thiotepa and carboplatin were used to develop the ANC model consisting of a drug-sensitive progenitor cell compartment, linked to the peripheral blood compartment, through three transition compartments. PBSC were incorporated into the first transit compartment following a zero-order process, k(in), and the rebound effect was explained by a feedback mechanism. A 'kinetics of drug action' model was used to quantify the HDC effect on the progenitor cells according to a linear function, with a slope (alpha). RESULTS: The typical of the ANC at baseline (Circ(0)), mean transit time (MTT), feedback parameter (gamma), k(in) and alpha were estimated to be 5,610 x 10(6)/L, 3.25 days, 0.145, 0.954 cell/kg/day and 2.50 h/U, respectively. rHuG-CSF shortens the MTT by 92% and increases the mitotic activity by 120%. Bootstrap analysis, visual predictive check and numerical predictive checks evidenced accurate prediction of the ANC nadir, time to ANC nadir and time to grade 4 neutropenia recovery. CONCLUSION: The time course of neutropenia following high-dose of chemotherapy and PBSC transplantation was accurately predicted. Higher amount of CD34+ cells in the PBSC transplantation and earlier administration rHuG-CSF were associated with faster haematological recovery.
PURPOSE: To describe the absolute neutrophil counts (ANC) profile in breast cancerpatients receiving high-dose of chemotherapy and peripheral blood stem-cells (PBSC) transplantation. METHODS: Data from 41 subjects receiving cyclophosphamide, thiotepa and carboplatin were used to develop the ANC model consisting of a drug-sensitive progenitor cell compartment, linked to the peripheral blood compartment, through three transition compartments. PBSC were incorporated into the first transit compartment following a zero-order process, k(in), and the rebound effect was explained by a feedback mechanism. A 'kinetics of drug action' model was used to quantify the HDC effect on the progenitor cells according to a linear function, with a slope (alpha). RESULTS: The typical of the ANC at baseline (Circ(0)), mean transit time (MTT), feedback parameter (gamma), k(in) and alpha were estimated to be 5,610 x 10(6)/L, 3.25 days, 0.145, 0.954 cell/kg/day and 2.50 h/U, respectively. rHuG-CSF shortens the MTT by 92% and increases the mitotic activity by 120%. Bootstrap analysis, visual predictive check and numerical predictive checks evidenced accurate prediction of the ANC nadir, time to ANC nadir and time to grade 4 neutropenia recovery. CONCLUSION: The time course of neutropenia following high-dose of chemotherapy and PBSC transplantation was accurately predicted. Higher amount of CD34+ cells in the PBSC transplantation and earlier administration rHuG-CSF were associated with faster haematological recovery.
Authors: P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard Journal: J Pharmacokinet Pharmacodyn Date: 2006-10-19 Impact factor: 2.745
Authors: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri H Roché; Jean-Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens Journal: Invest New Drugs Date: 2005-06 Impact factor: 3.850
Authors: A D Elias; L Ayash; K C Anderson; M Hunt; C Wheeler; G Schwartz; I Tepler; R Mazanet; C Lynch; S Pap Journal: Blood Date: 1992-06-01 Impact factor: 22.113
Authors: Wojciech Krzyzanski; John M Harrold; Liviawati S Wu; Juan Jose Perez-Ruixo Journal: J Pharmacokinet Pharmacodyn Date: 2016-09-09 Impact factor: 2.745
Authors: Mario González-Sales; Belén Valenzuela; Carlos Pérez-Ruixo; Carlos Fernández Teruel; Bernardo Miguel-Lillo; Arturo Soto-Matos; Juan Jose Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2012-11 Impact factor: 6.447
Authors: Murad Melhem; Isabelle Delor; Juan Jose Pérez-Ruixo; John Harrold; Andrew Chow; Liviawati Wu; Philippe Jacqmin Journal: Br J Clin Pharmacol Date: 2018-02-20 Impact factor: 4.335
Authors: Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2013-12 Impact factor: 6.447